AU2005210105A1 - Method of inducing or modulating immune response - Google Patents

Method of inducing or modulating immune response Download PDF

Info

Publication number
AU2005210105A1
AU2005210105A1 AU2005210105A AU2005210105A AU2005210105A1 AU 2005210105 A1 AU2005210105 A1 AU 2005210105A1 AU 2005210105 A AU2005210105 A AU 2005210105A AU 2005210105 A AU2005210105 A AU 2005210105A AU 2005210105 A1 AU2005210105 A1 AU 2005210105A1
Authority
AU
Australia
Prior art keywords
axotrophin
polynucleotide
polypeptide
derived
encoded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005210105A
Other languages
English (en)
Inventor
Susan Marie Metcalfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACLAR Ltd
Original Assignee
Aclar Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclar Ltd filed Critical Aclar Ltd
Publication of AU2005210105A1 publication Critical patent/AU2005210105A1/en
Assigned to ACLAR LIMITED reassignment ACLAR LIMITED Request for Assignment Assignors: METCALFE, SUSAN MARIE
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2005210105A 2004-01-29 2005-01-31 Method of inducing or modulating immune response Abandoned AU2005210105A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0402051.7A GB0402051D0 (en) 2004-01-29 2004-01-29 Fate determination in immunity
GB0402051.7 2004-01-29
PCT/EP2005/000934 WO2005074973A2 (en) 2004-01-29 2005-01-31 Method of inducing or modulating immune response

Publications (1)

Publication Number Publication Date
AU2005210105A1 true AU2005210105A1 (en) 2005-08-18

Family

ID=31971742

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005210105A Abandoned AU2005210105A1 (en) 2004-01-29 2005-01-31 Method of inducing or modulating immune response

Country Status (10)

Country Link
US (2) US20070286807A1 (cg-RX-API-DMAC7.html)
EP (1) EP1713495A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007523640A (cg-RX-API-DMAC7.html)
KR (1) KR20070007291A (cg-RX-API-DMAC7.html)
CN (1) CN1929855A (cg-RX-API-DMAC7.html)
AU (1) AU2005210105A1 (cg-RX-API-DMAC7.html)
CA (1) CA2560055A1 (cg-RX-API-DMAC7.html)
GB (1) GB0402051D0 (cg-RX-API-DMAC7.html)
WO (1) WO2005074973A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200606331B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402051D0 (en) * 2004-01-29 2004-03-03 Metcalfe Su Fate determination in immunity
ATE508207T1 (de) * 2006-02-28 2011-05-15 Charite Universitaetsmedizin Nachweis und qualitätskontrolle von regulator-t- zellen mittels dna-methylierungsanalyse des foxp3-gens
GB0614536D0 (en) * 2006-07-21 2006-08-30 Metcalfe Susan M Methods of controlling cellular response to LIF
GB0721081D0 (en) * 2007-10-26 2007-12-05 Metcalfe Susan M Immuno-modulatory composition
US20120164659A1 (en) * 2009-08-05 2012-06-28 Nexigen Gmbh Human hcv-interacting proteins and methods of use
WO2014031883A1 (en) 2012-08-23 2014-02-27 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
US11779683B2 (en) * 2019-04-08 2023-10-10 Loubert S. Suddaby Extended release immunomodulatory implant to facilitate bone morphogenesis
US11369473B2 (en) 2019-04-08 2022-06-28 Loubert S. Suddaby Extended release immunomodulatory implant to facilitate bone morphogenesis
CN112843222B (zh) * 2021-01-21 2023-01-31 暨南大学 Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
AU2003213606A1 (en) * 2002-03-01 2003-10-13 Exelixis, Inc. MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
GB0402051D0 (en) * 2004-01-29 2004-03-03 Metcalfe Su Fate determination in immunity

Also Published As

Publication number Publication date
KR20070007291A (ko) 2007-01-15
ZA200606331B (en) 2007-12-27
EP1713495A2 (en) 2006-10-25
WO2005074973A9 (en) 2006-10-26
GB0402051D0 (en) 2004-03-03
US20080125390A1 (en) 2008-05-29
WO2005074973A2 (en) 2005-08-18
JP2007523640A (ja) 2007-08-23
CA2560055A1 (en) 2005-08-18
WO2005074973A3 (en) 2005-12-08
CN1929855A (zh) 2007-03-14
US20070286807A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
JP6259012B2 (ja) 脱毛症の治療方法
AU2026202687A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
US20080125390A1 (en) Methods for Modulating Immune and Inflammatory Responses
EP0884947B1 (en) Dna vaccination for induction of suppressive t cell response
US20180303922A1 (en) Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
Zhang et al. Tumour necrosis factor‐α (TNF‐α) transgene‐expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T‐cell activation and anti‐tumour immunity than DCs generated in recombinant TNF‐α
RU2660580C2 (ru) Растворимый медиатор
KR20220100913A (ko) Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 신세포 암종(rcc) 치료법
Xu et al. A limited course of soluble CD83 delays acute cellular rejection of MHC‐mismatched mouse skin allografts
JP2023525084A (ja) 多発性硬化症の処置のためのペプチド及び方法
CA2468020A1 (en) Osteopontin-related compositions and methods
Thistlethwaite et al. Adoptive transfer of Treg depleted autologous T cells in advanced renal cell carcinoma
US9289469B2 (en) Depleting immunosuppressive monocytes within a mammal
EP3402508A1 (en) Methods and compositions for modulating thymic function
KR101949186B1 (ko) 면역 유도제
CN121127257A (zh) 携带kras结合蛋白并敲除内源性tcr的宿主细胞及其使用方法
WO2022267842A1 (en) Disruptions of pdcd1, adora2a, and ctla4 genes and uses thereof
Ishida et al. Immune dysfunctions and activation of natural killer cells in human IL-2 and IL-2/IL-2 receptor L-chain transgenic mice
Fernandez et al. Immune status assay (ISA): a noninvasive procedure for studying allograft rejection
Zhou et al. Endogenous C3 expression affects the potency of macrophages as stimulators of T cell alloreactivity
Singer et al. Inhibition of T Cell Activation Through Interruption of Adaptor Protein Associations
Bentlejwesky et al. KINETICS OF T CELL MEMORY RECOVERY IN LUNG TRANSPLANT RECIPIENTS TREATED WITH T CELL DEPLETION THERAPIES
Demirkiran et al. LIVER ALLOGRAFT REJECTION IS ASSOCIATED WITH LOW LEVELS OF REGULATORY T-CELLS IN PERIPHERAL BLOOD
Moore et al. FIBRONECTIN-ALPHA-4 BETA-1 INTEGRIN INTERACTIONS INHIBIT p42/44 MAPK PHOSPHORILATION AND UP-REGULATE GELATINASE-B EXPRESSION/ACTIVATION BY LEUKOCYTES IN STEATOTIC LIVER COLD ISCHEMIA/REPERFUSION INJURY
Azimzadeh et al. MODULATION OF IMMUNE RESPONSES TO HEART ALLOGRAFTS BY DONOR BONE MARROW INFUSION IN MONKEYS TREATED WITH CD154 COSTIMULATION BLOCKADE

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ACLAR LIMITED

Free format text: FORMER APPLICANT(S): METCALFE, SUSAN MARIE

MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination